Rosnilimab (Mouse IgG2a)
Based on 1 Customer Validation
Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a antibody, Rosnilimab. Rosnilimab is a PD-1 agonistic monoclonal antibody. Rosnilimab (Mouse IgG2a) optimizes the inhibitory PD-1 signaling pathway without blocking PD-L1 binding; it also activates moderately activated PD-1+ T cells and eliminates PD-1high cells, Tfh/Tph cells and Teff cells. Rosnilimab (Mouse IgG2a) reduces the secretion and gene expression of IFN-γ, CXCL13, IL-6 and TNF, decreases macrophage infiltration, and downregulates the gene expression of inflammatory myeloid cells. Rosnilimab (Mouse IgG2a) can be used in studies related to ulcerative colitis.
For research use only. We do not sell to patients.
- Purity: 98.0%
- Molecular Weight:147.527 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Mouse IgG2a kappa
Human
|
PD-1 |
IFN-γ |
CXCL13 |
IL-6 |
TNF |
Rosnilimab (Mouse IgG2a) (10 mg/kg; i.p.; twice weekly; 4 weeks) reduces pathogenic T cell and proinflammatory macrophage infiltration, and downregulates an inflammatory myeloid gene signature overlapping with human UC, in an adoptive transfer murine model of colitis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rag2-/- recipients, hPD-1 transgenic donor mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice weekly; 4 weeks
-
Result:Maintained body weight compared to isotype control.
Reduced colonic inflammation measured by histological pathology score.
Reduced the number and percentage of CD4+ T cells in the colon.
Reduced colonic gene expression of Ifng and Cxcl13 compared to isotype control.
-
Animal Model:Rag2-/- (recipient); hPD-1 transgenic (donor, adoptive transfer of hPD1 CD4+CD45Rb+ T cells into Rag2-/- recipients to induce colitis)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice weekly; 4 weeks
-
Result:Reduced CD4+ T cell infiltration into the mouse colon.
Downregulated 399 myeloid genes that overlap with a human UC inflammatory myeloid gene signature and genes upregulated in mouse colitis colon tissue.
Reduced colon tissue expression of inflammatory cytokine genes Il6, Tnf, and Ifng.
Reduced counts of infiltrating M1 and M2B macrophages in colon tissue.
Decreased colon tissue expression of macrophage recruiting chemokine/receptor genes Ccl2 and Ccr2, inflammatory monocyte marker gene Cd14, pathogen detection genes Tlr2 and Tlr4, and immune activation/amplification genes Cd80, Cd86, Myd88, and Trem1.
PDCD1/PD-1/CD279
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Molecular Weight 147.527 kDa
-
Color Colorless to light yellow
-
SMILES
[Rosnilimab (Mouse IgG2a)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rosnilimab (Mouse IgG2a) Related Classifications
HY-P9S0062 Related Classifications
Powered by Bioz